Literature DB >> 12838516

Hereditary motor and sensory neuropathy with agenesis of the corpus callosum.

Nicolas Dupré1, Heidi C Howard, Jean Mathieu, George Karpati, Michel Vanasse, Jean-Pierre Bouchard, Stirling Carpenter, Guy A Rouleau.   

Abstract

Hereditary motor and sensory neuropathy associated with agenesis of the corpus callosum (OMIM 218000) is an autosomal recessive disease of early onset characterized by a delay in developmental milestones, a severe sensory-motor polyneuropathy with areflexia, a variable degree of agenesis of the corpus callosum, amyotrophy, hypotonia, and cognitive impairment. Although this disorder has rarely been reported worldwide, it has a high prevalence in the Saguenay-Lac-St-Jean region of the province of Quebec (Canada) predominantly because of a founder effect. The gene defect responsible for this disorder recently has been identified, and it is a protein-truncating mutation in the SLC12A6 gene, which codes for a cotransporter protein known as KCC3. Herein, we provide the first extensive review of this disorder, covering epidemiological, clinical, and molecular genetic studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12838516     DOI: 10.1002/ana.77777

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  19 in total

Review 1.  Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.

Authors:  Tz-Chuen Ju; Yow-Sien Lin; Yijuang Chern
Journal:  Cell Mol Life Sci       Date:  2012-05-25       Impact factor: 9.261

2.  Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.

Authors:  Hélène Vézina; Francine Durocher; Martine Dumont; Louis Houde; Csilla Szabo; Martine Tranchant; Jocelyne Chiquette; Marie Plante; Rachel Laframboise; Jean Lépine; Heli Nevanlinna; Dominique Stoppa-Lyonnet; David Goldgar; Peter Bridge; Jacques Simard
Journal:  Hum Genet       Date:  2005-05-10       Impact factor: 4.132

3.  Complicated hereditary spastic paraplegia with thin corpus callosum: variation of phenotypic expression over time.

Authors:  Anne-Dörte Sperfeld; Jan Kassubek; Andrew H Crosby; Beate Winner; Albert C Ludolph; Ingo Uttner; C Oliver Hanemann
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

4.  Axonal and periaxonal swelling precede peripheral neurodegeneration in KCC3 knockout mice.

Authors:  Nellie Byun; Eric Delpire
Journal:  Neurobiol Dis       Date:  2007-06-23       Impact factor: 5.996

Review 5.  Clinical, genetic and imaging findings identify new causes for corpus callosum development syndromes.

Authors:  Timothy J Edwards; Elliott H Sherr; A James Barkovich; Linda J Richards
Journal:  Brain       Date:  2014-01-28       Impact factor: 13.501

Review 6.  Mutations affecting GABAergic signaling in seizures and epilepsy.

Authors:  Aristea S Galanopoulou
Journal:  Pflugers Arch       Date:  2010-03-30       Impact factor: 3.657

Review 7.  K-Cl cotransporters, cell volume homeostasis, and neurological disease.

Authors:  Kristopher T Kahle; Arjun R Khanna; Seth L Alper; Norma C Adragna; Peter K Lauf; Dandan Sun; Eric Delpire
Journal:  Trends Mol Med       Date:  2015-07-01       Impact factor: 11.951

8.  KCC3 axonopathy: neuropathological features in the central and peripheral nervous system.

Authors:  Roland N Auer; Janet L Laganière; Yves O Robitaille; John Richardson; Patrick A Dion; Guy A Rouleau; Masoud Shekarabi
Journal:  Mod Pathol       Date:  2016-05-27       Impact factor: 7.842

Review 9.  Physiology of SLC12 transporters: lessons from inherited human genetic mutations and genetically engineered mouse knockouts.

Authors:  Kenneth B Gagnon; Eric Delpire
Journal:  Am J Physiol Cell Physiol       Date:  2013-01-16       Impact factor: 4.249

10.  A deletion mutation in Slc12a6 is associated with neuromuscular disease in gaxp mice.

Authors:  Yan Jiao; Xiudong Jin; Jian Yan; Chi Zhang; Feng Jiao; Xinmin Li; Bruce A Roe; David B Mount; Weikuan Gu
Journal:  Genomics       Date:  2008-03-14       Impact factor: 5.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.